LAB INDEX

Showing search results for "Cytogenetic Abnormalities"

  • Impact
  • Papers
  • Jobs
  • Conferences
Name Impact
?

Papers Institution Country Funding

Levine, Ross L

585 20 Memorial Sloan-Kettering Cancer Center USA $5,481,400.00

Bloomfield, Clara D

575.1 19 The Ohio State University Comprehensive Cancer Center USA $5,706,939.00

Haferlach, Torsten

449.2 36 MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, Munich Germany -

Tefferi, Ayalew

366.1 28 Mayo Clinic USA -

Tien, H-F

364 19 National Taiwan University Hospital Taiwan -

Döhner, Konstanze

343.4 13 University Hospital of Ulm Germany -

Maciejewski, Jaroslaw P

338 21 Cleveland Clinic USA $9,230,615.00

Wilson, Richard K

257.1 2 Washington University USA $216,151,607.00

Mullighan, Charles G

247.1 13 University of California USA $4,986,633.00

van den Heuvel-Eibrink, M M

245.2 17 Erasmus MC-Sophia Children's Hospital Netherlands -

Ebert, Benjamin L

244.6 10 Harvard Medical School USA -

Graubert, Timothy A

229.5 5 Washington University School of Medicine USA $7,041,673.00

Tallman, Martin S

222.1 14 Roosevelt Hospital Center USA -

Bhatia, Ravi

220.5 6 Division of Hematopoietic Stem Cell and Leukemia Research and. N/A $4,251,368.00

Garcia-Manero, Guillermo

213.6 22 The University of Texas MD Anderson Cancer Center USA $292,600.00

Kantarjian, Hagop

212 19 The University of Texas M. D. Anderson Cancer Center USA $12,195,814.00

Meshinchi, Soheil

209.5 10 Clinical Research Division USA $1,905,477.00

Cortes, Jorge

208.9 27 The University of Texas MD Anderson Cancer Center USA $8,473,811.00

Weissman, Irving L

202.3 5 Stanford University USA $18,173,133.00

Ley, Timothy J

202.3 8 Washington University School of Medicine USA $28,223,390.00

Chen, Sai-Juan

198.2 8 Rui Jin Hospital affiliated with Shanghai Jiao Tong University School of Medicine China -

Ravandi, F

193.4 17 The University of Texas MD Anderson Cancer Center USA -

Döhner, Hartmut

192.3 6 Comprehensive Cancer Center USA -

Dombret, Hervé

190.1 11 Department of Hematology, Hôpital Edouard Herriot, Lyon France -

Estey, Elihu H

178.2 11 Stanford University School of Medicine USA -

Scott, Hamish S

177.6 2 Department of Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, South Australia Australia -

Falini, Brunangelo

177 8 Munich Leukemia Laboratory GmbH, Munich Germany -

Andreeff, M

170.2 12 University of Texas M. D. Anderson Cancer Center USA -

Kantarjian, Hagop M

165.3 12 MD Anderson Cancer Center USA -

Carroll, M

164 8 University of Pennsylvania USA -

Pabst, Thomas

161.4 7 University Hospital and University of Berne Switzerland -

Appelbaum, Frederick R

160.6 12 Stanford Cancer Center USA -

Campana, Dario

160.2 9 St Jude Children's Research Hospital USA $1,647,044.00

Hsu, Katharine C

159.9 1 Memorial Sloan-Kettering Cancer Center USA $3,245,354.00

Marcucci, Guido

156.6 9 The Ohio State University USA $7,902,249.00

Relling, Mary V

149.7 7 St Jude Children's Research Hospital USA $11,471,423.00

Armstrong, Scott A

148.4 7 Harvard Medical School USA $9,205,355.00

Stegmaier, Kimberly

147.9 4 Harvard Medical School USA $1,841,773.00

DiPersio, John F

147.5 3 Washington University School of Medicine USA $6,990,653.00

Scadden, David T

142.1 2 Massachusetts General Hospital USA $23,872,119.00

Weisdorf, Daniel J

140.3 13 Mayo Clinic Rochester USA $3,677,713.00

Sung, L

138 18 Children's Hospital of Eastern Ontario Canada -

Jansen, Joop H

136.3 3 Radboud University Nijmegen Medical Centre and Nijmegen Centre for Molecular Life Sciences Netherlands -

Melnick, Ari

135.9 3 Weill Cornell Medical College USA $6,068,155.00

Löwenberg, Bob

133.8 5 University Hospital La Fe Spain -

Heuser, Michael

132.6 10 Hannover Medical School Germany -

Björkholm, Magnus

130 3 Genetic Epidemiology Branch, DCEG, NCI, 6120 Executive Blvd, Room 7124, MSC 7236, Bethesda, MD 20892-7236 USA -

Pui, Ching-Hon

127.8 11 St Jude Children's Research Hospital USA -

Ganser, Arnold

125.9 7 Hannover Medical School Germany -

Delwel, Ruud

124.4 7 Erasmus University Medical Center Netherlands -
Name Institution Date Impact Publication

Tefferi, Ayalew

Mayo Clinic 04/15/2009 101.70 CA: a cancer journal for clinicians
Advances in understanding and management of myeloproliferative neoplasms. Abstract

Hsu, Katharine C

Memorial Sloan-Kettering Cancer Center 08/30/2012 53.29 The New England journal of medicine
HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. Abstract

Graubert, Timothy A

Washington University School of Medicine 03/14/2012 53.29 The New England journal of medicine
Clonal architecture of secondary acute myeloid leukemia. Abstract

Levine, Ross L

Memorial Sloan-Kettering Cancer Center 03/14/2012 53.29 The New England journal of medicine
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. Abstract

Ebert, Benjamin L

Harvard Medical School 06/30/2011 53.29 The New England journal of medicine
Clinical effect of point mutations in myelodysplastic syndromes. Abstract

Falini, Brunangelo

University of Perugia 06/11/2011 53.29 The New England journal of medicine
BRAF mutations in hairy-cell leukemia. Abstract

Pabst, Thomas

Universitätsspital Basel , Basel 03/17/2011 53.29 The New England journal of medicine
Cytarabine dose for acute myeloid leukemia. Abstract

Wilson, Richard K

Washington University 11/10/2010 53.29 The New England journal of medicine
DNMT3A mutations in acute myeloid leukemia. Abstract

Tallman, Martin S

Israel Institute of Technology 09/24/2009 53.29 The New England journal of medicine
Anthracycline dose intensification in acute myeloid leukemia. Abstract

Ley, Timothy J

Washington University Medical School 08/05/2009 53.29 The New England journal of medicine
Recurring mutations found by sequencing an acute myeloid leukemia genome. Abstract

Relling, Mary V

St Jude Children's Research Hospital 06/25/2009 53.29 The New England journal of medicine
Treating childhood acute lymphoblastic leukemia without cranial irradiation. Abstract

Mullighan, Charles G

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105 03/22/2013 38.27 Lancet
Acute lymphoblastic leukaemia. Abstract

Levine, Ross L

Memorial Sloan-Kettering Cancer Center 08/17/2012 37.54 Nature reviews. Cancer
The role of mutations in epigenetic regulators in myeloid malignancies. Abstract

DiPersio, John F

Washington University School of Medicine 01/11/2012 36.28 Nature
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Abstract

Mullighan, Charles G

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105 01/11/2012 36.28 Nature
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Abstract

Maciejewski, Jaroslaw P

Cleveland Clinic 07/07/2013 35.53 Nature genetics
Somatic SETBP1 mutations in myeloid malignancies. Abstract

Levine, Ross L

Memorial Sloan-Kettering Cancer Center 09/23/2012 35.53 Nature genetics
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Abstract

Scott, Hamish S

Department of Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, South Australia 12/27/2011 35.53 Nature genetics
Spliceosome mutations in hematopoietic malignancies. Abstract

Scott, Hamish S

Department of Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, South Australia 09/04/2011 35.53 Nature genetics
Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Abstract

Chen, Sai-Juan

Rui Jin Hospital affiliated with Shanghai Jiao Tong University School of Medicine 03/13/2011 35.53 Nature genetics
Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Abstract

Jansen, Joop H

Radboud University Nijmegen Medical Centre and Nijmegen Centre for Molecular Life Sciences 07/04/2010 35.53 Nature genetics
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Abstract

Levine, Ross L

Memorial Sloan-Kettering Cancer Center 08/27/2009 35.53 Nature genetics
Inherited susceptibility to pediatric acute lymphoblastic leukemia. Abstract

Mullighan, Charles G

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105 06/26/2009 35.53 Nature genetics
TET2 mutations in myelodysplasia and myeloid malignancies. Abstract

Jansen, Joop H

Radboud University Nijmegen Medical Centre and Nijmegen Centre for Molecular Life Sciences 05/31/2009 35.53 Nature genetics
Acquired mutations in TET2 are common in myelodysplastic syndromes. Abstract

Wilson, Richard K

Washington University 07/23/2012 32.40 Cell
The origin and evolution of mutations in acute myeloid leukemia. Abstract

Scadden, David T

Massachusetts General Hospital 09/02/2011 32.40 Cell
AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Abstract

Weissman, Irving L

Stanford University 07/27/2009 32.40 Cell
CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Abstract

Weissman, Irving L

Stanford University School of Medicine 07/27/2009 32.40 Cell
CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Abstract

Armstrong, Scott A

Harvard Medical School 03/26/2010 31.20 Science (New York, N.Y.)
The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Abstract

Relling, Mary V

St Jude Children's Research Hospital 01/29/2009 30.02 JAMA
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. Abstract

Ebert, Benjamin L

Harvard Medical School 06/13/2013 26.56 Cancer cell
In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Abstract

Mullighan, Charles G

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105 08/17/2012 26.56 Cancer cell
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Abstract

Levine, Ross L

Memorial Sloan-Kettering Cancer Center 08/17/2012 26.56 Cancer cell
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Abstract

Bhatia, Ravi

Division of Hematopoietic Stem Cell and Leukemia Research, City of Hope National Medical Center, Duarte, CA 91010 04/20/2012 26.56 Cancer cell
Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Abstract

Bhatia, Ravi

Division of Hematopoietic Stem Cell and Leukemia Research, City of Hope National Medical Center, Duarte, CA 91010 02/20/2012 26.56 Cancer cell
Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Abstract

Bhatia, Ravi

Division of Hematopoietic Stem Cell and Leukemia Research and. 11/18/2011 26.56 Cancer cell
Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk. Abstract

Ebert, Benjamin L

Harvard Medical School 11/18/2011 26.56 Cancer cell
Power cut: inhibiting mitochondrial translation to target leukemia. Abstract

Carroll, Martin

University of Pennsylvania 09/12/2011 26.56 Cancer cell
Short hairpin RNA screen reveals bromodomain proteins as novel targets in acute myeloid leukemia. Abstract

Mullighan, Charles G

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105 07/11/2011 26.56 Cancer cell
The role of TET2 in hematologic neoplasms. Abstract

Armstrong, Scott A

Harvard Medical School 07/11/2011 26.56 Cancer cell
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Abstract

Levine, Ross L

Memorial Sloan-Kettering Cancer Center 06/30/2011 26.56 Cancer cell
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Abstract

Weissman, Irving L

Stanford University School of Medicine 01/21/2011 26.56 Cancer cell
Human acute myelogenous leukemia stem cells revisited: there's more than meets the eye. Abstract

Melnick, Ari

Weill Cornell Medical College 12/09/2010 26.56 Cancer cell
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Abstract

Mullighan, Charles G

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105 10/18/2010 26.56 Cancer cell
T-lineage lymphoblastic lymphoma and leukemia-a MASSive problem. Abstract

Marcucci, Guido

The Ohio State University 04/13/2010 26.56 Cancer cell
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Abstract

Armstrong, Scott A

Harvard Medical School 02/04/2010 26.56 Cancer cell
HELP for AML: methylation profiling opens new avenues. Abstract

Melnick, Ari

Weill Cornell Medical College 01/07/2010 26.56 Cancer cell
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Abstract

Stegmaier, Kimberly

Harvard Medical School 10/05/2009 26.56 Cancer cell
Proteomic and genetic approaches identify Syk as an AML target. Abstract

Pui, Ching-Hon

St Jude Children's Research Hospital 02/02/2009 26.56 Cancer cell
T cell acute lymphoblastic leukemia: NOTCHing the way toward a better treatment outcome. Abstract

Levine, Ross L

Memorial Sloan-Kettering Cancer Center 04/09/2012 25.42 Cell stem cell
Targeting β-catenin in CML: leukemia stem cells beware! Abstract

Campana, Dario

National University of Singapore 05/05/2010 22.58 The Lancet. Oncology
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Abstract

Campana, Dario

National University of Singapore 01/13/2009 22.58 The Lancet. Oncology
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Abstract

Scadden, David T

Massachusetts General Hospital 10/27/2013 22.46 Nature medicine
Differential regulation of myeloid leukemias by the bone marrow microenvironment. Abstract

Ebert, Benjamin L

Harvard Medical School 08/28/2012 20.00 Annual review of pathology
Molecular pathophysiology of myelodysplastic syndromes. Abstract

Bloomfield, Clara D

The Ohio State University Comprehensive Cancer Center 12/30/2013 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. Abstract

Bloomfield, Clara D

The Ohio State University 05/06/2013 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. Abstract

Pui, Ching-Hon

St Jude Children's Research Hospital 05/06/2013 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia. Abstract

Dombret, Hervé

Department of Hematology, Hôpital Edouard Herriot, Lyon 12/17/2012 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. Abstract

Kantarjian, Hagop

The University of Texas M. D. Anderson Cancer Center 11/19/2012 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. Abstract

Delwel, Ruud

Erasmus University Medical Center 09/24/2012 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. Abstract

Bloomfield, Clara D

The Ohio State University 09/17/2012 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. Abstract

Campana, Dario

National University of Singapore 09/10/2012 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. Abstract

Ebert, Benjamin L

Harvard Medical School 08/06/2012 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. Abstract

Bloomfield, Clara D

The Ohio State University Comprehensive Cancer Center 07/02/2012 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. Abstract

Kantarjian, Hagop M

MD Anderson Cancer Center 05/14/2012 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. Abstract

Kantarjian, Hagop M

The University of Texas MD Anderson Cancer Center 05/14/2012 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. Abstract

Löwenberg, Bob

University Hospital La Fe 05/07/2012 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. Abstract

Döhner, Konstanze

University Hospital of Ulm 03/19/2012 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. Abstract

Maciejewski, Jaroslaw P

Cleveland Clinic 02/27/2012 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. Abstract

Bloomfield, Clara D

The Ohio State University 01/30/2012 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. Abstract

Björkholm, Magnus

Genetic Epidemiology Branch, DCEG, NCI, 6120 Executive Blvd, Room 7124, MSC 7236, Bethesda, MD 20892-7236 12/12/2011 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes. Abstract

Estey, Elihu H

Stanford University School of Medicine 10/03/2011 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. Abstract

van den Heuvel-Eibrink, Marry M

Erasmus MC-Sophia Children's Hospital 09/26/2011 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 07/11/2011 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Abstract

Heuser, Michael

Hannover Medical School 06/13/2011 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. Abstract

Ganser, Arnold

Hannover Medical School 05/16/2011 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. Abstract

Ravandi, Farhad

M.D. Anderson Cancer Center 05/09/2011 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. Abstract

Döhner, Konstanze

University Hospital of Ulm 05/09/2011 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. Abstract

Bloomfield, Clara D

The Ohio State University Comprehensive Cancer Center 02/22/2011 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. Abstract

Döhner, Konstanze

University Hospital of Ulm 02/22/2011 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. Abstract

Ebert, Benjamin L

Harvard Medical School 01/10/2011 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Unraveling the molecular pathophysiology of myelodysplastic syndromes. Abstract

Döhner, Hartmut

Comprehensive Cancer Center 01/10/2011 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. Abstract

Heuser, Michael

Hannover Medical School 01/04/2011 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. Abstract

Meshinchi, Soheil

Clinical Research Division 12/28/2010 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group. Abstract

Relling, Mary V

St Jude Children's Research Hospital 12/20/2010 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Improved prognosis for older adolescents with acute lymphoblastic leukemia. Abstract

Bloomfield, Clara D

The Ohio State University 11/15/2010 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Abstract

Döhner, Hartmut

Universitätsklinikum Ulm, Ulm 08/30/2010 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. Abstract

Döhner, Hartmut

Comprehensive Cancer Center 07/26/2010 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. Abstract

Kantarjian, Hagop M

The University of Texas M. D. Anderson Cancer Center 07/26/2010 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. Abstract

Haferlach, Torsten

MLL Munich Leukemia Laboratory, Munich 07/19/2010 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. Abstract

Döhner, Konstanze

University Hospital of Ulm 07/12/2010 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. Abstract

Döhner, Konstanze

University Hospital of Ulm 06/21/2010 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. Abstract

Meshinchi, Soheil

Clinical Research Division 04/26/2010 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group. Abstract

Bloomfield, Clara D

The Ohio State University 04/05/2010 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Abstract

Delwel, Ruud

Erasmus University Medical Center 03/22/2010 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. Abstract

Estey, Elihu H

Clinical Research Division and Southwest Oncology Group Statistical Center 02/16/2010 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. Abstract

DiPersio, John F

Washington University School of Medicine 12/21/2009 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. Abstract

Bloomfield, Clara D

The Ohio State University 12/21/2009 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. Abstract

Kantarjian, Hagop

The University of Texas M. D. Anderson Cancer Center 12/14/2009 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. Abstract

Kantarjian, Hagop

The University of Texas M. D. Anderson Cancer Center 12/14/2009 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. Abstract

Maciejewski, Jaroslaw P

Cleveland Clinic 11/09/2009 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. Abstract

Relling, Mary V

St Jude Children's Research Hospital 11/09/2009 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 11/02/2009 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. Abstract

Löwenberg, Bob

University Hospital La Fe 10/26/2009 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. Abstract

Maciejewski, Jaroslaw P

Cleveland Clinic 09/21/2009 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. Abstract

Kantarjian, Hagop M

The University of Texas M. D. Anderson Cancer Center 08/31/2009 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. Abstract

Andreeff, Michael

The University of Texas MD Anderson Cancer Center 08/03/2009 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. Abstract

Weisdorf, Daniel J

University of Minnesota 07/06/2009 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. Abstract

Ganser, Arnold

Hannover Medical School 04/20/2009 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. Abstract

Björkholm, Magnus

Genetic Epidemiology Branch, DCEG, NCI, 6120 Executive Blvd, Room 7124, MSC 7236, Bethesda, MD 20892-7236 03/16/2009 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Socioeconomic differences in patient survival are increasing for acute myeloid leukemia and multiple myeloma in sweden. Abstract

Bhatia, Ravi

Division of Hematopoietic Stem Cell and Leukemia Research and. 01/05/2009 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. Abstract

Dombret, Hervé

Department of Hematology, Hôpital Edouard Herriot, Lyon 01/05/2009 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. Abstract

Kantarjian, Hagop

The University of Texas M. D. Anderson Cancer Center 12/15/2008 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. Abstract

Levine, Ross L

Memorial Sloan-Kettering Cancer Center 11/11/2013 13.85 The Journal of experimental medicine
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. Abstract

Levine, Ross L

Memorial Sloan-Kettering Cancer Center 04/05/2010 13.85 The Journal of experimental medicine
Metabolism and the leukemic stem cell. Abstract

Pui, C H

St Jude Children's Research Hospital 08/27/2012 13.75 Journal of the National Cancer Institute
Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia. Abstract

Levine, Ross L

Memorial Sloan-Kettering Cancer Center 09/03/2013 13.06 The Journal of clinical investigation
Isocitrate dehydrogenase mutations in leukemia. Abstract

Andreeff, Michael

The University of Texas MD Anderson Cancer Center 05/08/2013 13.06 The Journal of clinical investigation
CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. Abstract

Mullighan, Charles G

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105 10/01/2012 13.06 The Journal of clinical investigation
Molecular genetics of B-precursor acute lymphoblastic leukemia. Abstract

Stegmaier, Kimberly

Harvard Medical School 02/13/2012 13.06 The Journal of clinical investigation
The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia. Abstract

Ley, Timothy J

Siteman Cancer Center 05/31/2011 13.06 The Journal of clinical investigation
PML-RARA can increase hematopoietic self-renewal without causing a myeloproliferative disease in mice. Abstract

Levine, Ross L

Memorial Sloan-Kettering Cancer Center 03/23/2011 13.06 The Journal of clinical investigation
Finding a needle in a haystack: whole genome sequencing and mutation discovery in murine models. Abstract

Ley, Timothy J

Siteman Cancer Center 03/23/2011 13.06 The Journal of clinical investigation
Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. Abstract

Carroll, Martin

University of Pennsylvania 12/13/2010 13.06 The Journal of clinical investigation
BCR-ABL kinase is dead; long live the CML stem cell. Abstract

Carroll, Martin

University of Pennsylvania 12/13/2010 13.06 The Journal of clinical investigation
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. Abstract

Andreeff, Michael

University of Texas MD Anderson Cancer Center 12/21/2009 13.06 The Journal of clinical investigation
Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. Abstract

Ley, Timothy J

Washington University Medical School 05/18/2009 13.06 The Journal of clinical investigation
High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. Abstract

Heuser, Michael

Hannover Medical School 12/13/2013 9.90 Blood
Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Abstract

Maciejewski, Jaroslaw P

Cleveland Clinic 10/22/2013 9.90 Blood
Deep sequencing of the T-cell receptor repertoire in CD8+ T-large granular lymphocyte leukemia identifies signature landscapes. Abstract

Appelbaum, Frederick R

and University of Washington School of Medicine 10/03/2013 9.90 Blood
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Abstract

Marcucci, Guido

The Ohio State University 10/01/2013 9.90 Blood
Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease. Abstract

van den Heuvel-Eibrink, Marry M

Erasmus MC-Sophia Children's Hospital 08/23/2013 9.90 Blood
Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group. Abstract

Heuser, Michael

Hannover Medical School 08/16/2013 9.90 Blood
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Abstract

Bhatia, Ravi

Division of Hematopoietic Stem Cell and Leukemia Research and. 07/29/2013 9.90 Blood
The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. Abstract

Garcia-Manero, Guillermo

The University of Texas MD Anderson Cancer Center 07/29/2013 9.90 Blood
Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Abstract

Appelbaum, Frederick R

Clinical Research Division 07/11/2013 9.90 Blood
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Abstract

Andreeff, Michael

University of Texas MD Anderson Cancer Center 06/05/2013 9.90 Blood
Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment. Abstract

Döhner, Konstanze

University Hospital of Ulm 05/23/2013 9.90 Blood
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Abstract

Levine, Ross L

Memorial Sloan-Kettering Cancer Center 05/03/2013 9.90 Blood
Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Abstract

Döhner, Konstanze

University Hospital of Ulm 04/30/2013 9.90 Blood
Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Abstract

Andreeff, Michael

The University of Texas MD Anderson Cancer Center 04/05/2013 9.90 Blood
Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Abstract

Tien, Hwei-Fang

National Taiwan University Hospital 02/28/2013 9.90 Blood
Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. Abstract

Löwenberg, Bob

University Hospital La Fe 01/04/2013 9.90 Blood
Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Abstract

Döhner, Konstanze

University Hospital of Ulm 10/31/2012 9.90 Blood
Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Abstract

Marcucci, Guido

The Ohio State University 10/25/2012 9.90 Blood
Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Abstract

Kantarjian, Hagop

The University of Texas M. D. Anderson Cancer Center 10/15/2012 9.90 Blood
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Abstract

Löwenberg, Bob

University Hospital La Fe 10/09/2012 9.90 Blood
Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). Abstract

Tefferi, Ayalew

Mayo Clinic 09/11/2012 9.90 Blood
SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Abstract

Tien, Hwei-Fang

National Taiwan University Hospital 08/29/2012 9.90 Blood
The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Abstract

Pabst, Thomas

Universitätsspital Basel , Basel 08/22/2012 9.90 Blood
The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase-dependent cleavage of calreticulin in AML patients. Abstract

van den Heuvel-Eibrink, Marry M

Erasmus MC-Sophia Children's Hospital 08/09/2012 9.90 Blood
Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Abstract

Jansen, Joop H

Radboud University Nijmegen Medical Centre and Nijmegen Centre for Molecular Life Sciences 07/11/2012 9.90 Blood
High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia. Abstract

Relling, Mary V

St Jude Children's Research Hospital 06/22/2012 9.90 Blood
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Abstract

Meshinchi, Soheil

Clinical Research Division 05/30/2012 9.90 Blood
Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Abstract

Maciejewski, Jaroslaw P

Cleveland Clinic 05/02/2012 9.90 Blood
Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Abstract

Campana, Dario

St Jude Children's Research Hospital 04/19/2012 9.90 Blood
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Abstract

Delwel, Ruud

Erasmus University Medical Center 04/05/2012 9.90 Blood
Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Abstract

Haferlach, Torsten

University Cancer Center Hamburg 03/22/2012 9.90 Blood
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity. Abstract

Kantarjian, Hagop

The University of Texas M. D. Anderson Cancer Center 03/19/2012 9.90 Blood
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Abstract

Heuser, Michael

Hannover Medical School 03/02/2012 9.90 Blood
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Abstract

Meshinchi, Soheil

Clinical Research Division 02/29/2012 9.90 Blood
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Abstract

Maciejewski, Jaroslaw P

Cleveland Clinic 02/09/2012 9.90 Blood
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Abstract

Chen, Sai-Juan

Rui Jin Hospital affiliated with Shanghai Jiao Tong University School of Medicine 02/07/2012 9.90 Blood
Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia. Abstract

DiPersio, John F

Washington University School of Medicine 02/02/2012 9.90 Blood
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 01/06/2012 9.90 Blood
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Abstract

Haferlach, Torsten

MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, Munich 12/29/2011 9.90 Blood
Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. Abstract

Döhner, Hartmut

Universitätsklinikum Ulm, Ulm 12/20/2011 9.90 Blood
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Abstract

Tallman, Martin S

From 1City of Hope Comprehensive Cancer Center; 2Memorial Sloan-Kettering Cancer Center; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washingt… 12/16/2011 9.90 Blood
"Boldness be my friend" (Shakespeare; Cymbeline). Abstract

Relling, Mary V

St Jude Children's Research Hospital 11/23/2011 9.90 Blood
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Abstract

Dombret, Hervé

Department of Hematology, Hôpital Edouard Herriot, Lyon 11/18/2011 9.90 Blood
Gene mutation and AML pathogenesis. Abstract

Tefferi, Ayalew

Mayo Clinic 11/17/2011 9.90 Blood
SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Abstract

Tien, Hwei-Fang

National Taiwan University Hospital 11/10/2011 9.90 Blood
DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Abstract

Bloomfield, Clara D

The Ohio State University Comprehensive Cancer Center 10/26/2011 9.90 Blood
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Abstract

Falini, Brunangelo

Munich Leukemia Laboratory GmbH, Munich 10/19/2011 9.90 Blood
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Abstract

Kantarjian, Hagop

The University of Texas M. D. Anderson Cancer Center 10/05/2011 9.90 Blood
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Abstract

Sung, Lillian

The Hospital for Sick Children 09/21/2011 9.90 Blood
Lack of clarity in the definition of treatment-related mortality: pediatric acute leukemia and adult acute promyelocytic leukemia as examples. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 09/16/2011 9.90 Blood
Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Abstract

Chen, Sai-Juan

Rui Jin Hospital affiliated with Shanghai Jiao Tong University School of Medicine 08/31/2011 9.90 Blood
Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Abstract

Meshinchi, Soheil

Clinical Research Division 08/26/2011 9.90 Blood
Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG. Abstract

Garcia-Manero, Guillermo

The University of Texas MD Anderson Cancer Center 08/25/2011 9.90 Blood
Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 08/16/2011 9.90 Blood
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Abstract

Bloomfield, Clara D

The Ohio State University Comprehensive Cancer Center 08/09/2011 9.90 Blood
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Abstract

Tien, Hwei-Fang

National Taiwan University Hospital 08/09/2011 9.90 Blood
TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Abstract

Maciejewski, Jaroslaw P

Cleveland Clinic 08/09/2011 9.90 Blood
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Abstract

Tallman, Martin S

From 1City of Hope Comprehensive Cancer Center; 2Memorial Sloan-Kettering Cancer Center; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washingt… 07/29/2011 9.90 Blood
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 07/29/2011 9.90 Blood
The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Abstract

Dombret, Hervé

Department of Hematology, Hôpital Edouard Herriot, Lyon 06/20/2011 9.90 Blood
Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Abstract

Appelbaum, Frederick R

Clinical Research Division 06/16/2011 9.90 Blood
Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Abstract

Pui, Ching-Hon

St Jude Children's Research Hospital 05/25/2011 9.90 Blood
High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Abstract

van den Heuvel-Eibrink, Marry M

Erasmus MC-Sophia Children's Hospital 05/06/2011 9.90 Blood
Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Abstract

Pabst, Thomas

University Hospital and University of Berne 04/06/2011 9.90 Blood
Protein disulfide isomerase blocks CEBPA translation and is up-regulated during the unfolded protein response in AML. Abstract

Tefferi, Ayalew

Mayo Clinic 03/30/2011 9.90 Blood
Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. Abstract

Tallman, Martin S

Israel Institute of Technology 03/17/2011 9.90 Blood
Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. Abstract

Ganser, Arnold

Hannover Medical School 03/03/2011 9.90 Blood
Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Abstract

Maciejewski, Jaroslaw P

Cleveland Clinic 02/23/2011 9.90 Blood
CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Abstract

Maciejewski, Jaroslaw P

Cleveland Clinic 02/01/2011 9.90 Blood
Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Abstract

Ley, Timothy J

Siteman Cancer Center 12/29/2010 9.90 Blood
Rara haploinsufficiency modestly influences the phenotype of acute promyelocytic leukemia in mice. Abstract

Döhner, Konstanze

University Hospital of Ulm 12/21/2010 9.90 Blood
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Abstract

Haferlach, Torsten

MLL Munich Leukemia Laboratory, Munich 12/09/2010 9.90 Blood
RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Abstract

Döhner, Konstanze

University Hospital of Ulm 12/02/2010 9.90 Blood
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Abstract

Weisdorf, Daniel J

Mayo Clinic Rochester 11/22/2010 9.90 Blood
Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Abstract

Bloomfield, Clara D

The Ohio State University Comprehensive Cancer Center 11/02/2010 9.90 Blood
The prognostic and functional role of microRNAs in acute myeloid leukemia. Abstract

van den Heuvel-Eibrink, Marry M

Erasmus MC-Sophia Children's Hospital 11/02/2010 9.90 Blood
High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23). Abstract

Haferlach, Torsten

University Cancer Center Hamburg 10/28/2010 9.90 Blood
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Abstract

Delwel, Ruud

Erasmus University Medical Center 09/20/2010 9.90 Blood
Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Abstract

Haferlach, Torsten

University Cancer Center Hamburg 08/30/2010 9.90 Blood
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Abstract

Tallman, Martin S

From 1City of Hope Comprehensive Cancer Center; 2Memorial Sloan-Kettering Cancer Center; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washingt… 08/17/2010 9.90 Blood
Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Abstract

Tien, Hwei-Fang

National Taiwan University Hospital 08/06/2010 9.90 Blood
Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Abstract

Bloomfield, Clara D

The Ohio State University Comprehensive Cancer Center 07/23/2010 9.90 Blood
FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Abstract

Ley, Timothy J

Siteman Cancer Center 07/20/2010 9.90 Blood
A protease-resistant PML-RAR{alpha} has increased leukemogenic potential in a murine model of acute promyelocytic leukemia. Abstract

Falini, Brunangelo

University of Perugia 07/15/2010 9.90 Blood
CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Abstract

Haferlach, Torsten

University Cancer Center Hamburg 06/25/2010 9.90 Blood
Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NO Abstract

Appelbaum, Frederick R

Stanford Cancer Center 06/18/2010 9.90 Blood
Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Abstract

Tallman, Martin S

Israel Institute of Technology 06/17/2010 9.90 Blood
How I treat acute myeloid leukemia. Abstract

Estey, Elihu H

Clinical Research Division and Southwest Oncology Group Statistical Center 06/10/2010 9.90 Blood
Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Abstract

Weisdorf, Daniel J

University of Minnesota 06/10/2010 9.90 Blood
Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Abstract

Bloomfield, Clara D

The Ohio State University 05/04/2010 9.90 Blood
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Abstract

Ganser, Arnold

Hannover Medical School 04/26/2010 9.90 Blood
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Abstract

Meshinchi, Soheil

Clinical Research Division 04/22/2010 9.90 Blood
Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Abstract

Tien, Hwei-Fang

National Taiwan University Hospital 04/05/2010 9.90 Blood
WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Abstract

Haferlach, Torsten

MLL Munich Leukemia Laboratory, Munich 03/04/2010 9.90 Blood
Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Abstract

Tien, Hwei-Fang

National Taiwan University Hospital 01/22/2010 9.90 Blood
Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Abstract

Meshinchi, Soheil

Clinical Research Division 01/07/2010 9.90 Blood
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Abstract

Weisdorf, Daniel J

Mayo Clinic Rochester 12/23/2009 9.90 Blood
Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Abstract

Maciejewski, Jaroslaw P

Cleveland Clinic 12/11/2009 9.90 Blood
Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. Abstract

Tefferi, Ayalew

Mayo Clinic 11/09/2009 9.90 Blood
International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Abstract

Estey, Elihu H

Clinical Research Division and Southwest Oncology Group Statistical Center 10/30/2009 9.90 Blood
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Abstract

Tien, Hwei-Fang

National Taiwan University Hospital 10/06/2009 9.90 Blood
AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Abstract

Appelbaum, Frederick R

Clinical Research Division 09/28/2009 9.90 Blood
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Abstract

Tefferi, Ayalew

Mayo Clinic 08/27/2009 9.90 Blood
Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Abstract

Carroll, Martin

University of Pennsylvania 08/21/2009 9.90 Blood
Taking aim at protein translation in AML. Abstract

Melnick, Ari

Weill Cornell Medical College 08/03/2009 9.90 Blood
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Abstract

Haferlach, Torsten

MLL Munich Leukemia Laboratory, Munich 07/08/2009 9.90 Blood
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 06/16/2009 9.90 Blood
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Abstract

van den Heuvel-Eibrink, Marry M

Erasmus MC-Sophia Children's Hospital 06/15/2009 9.90 Blood
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Abstract

Haferlach, Torsten

University Cancer Center Hamburg 05/14/2009 9.90 Blood
Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Abstract

Falini, Brunangelo

Munich Leukemia Laboratory GmbH, Munich 05/08/2009 9.90 Blood
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Abstract

Levine, Ross L

Memorial Sloan-Kettering Cancer Center 05/06/2009 9.90 Blood
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 05/04/2009 9.90 Blood
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Abstract

Stegmaier, Kimberly

Harvard Medical School 04/17/2009 9.90 Blood
Identification of AML1-ETO modulators by chemical genomics. Abstract

Maciejewski, Jaroslaw P

Cleveland Clinic 04/16/2009 9.90 Blood
Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Abstract

Tallman, Martin S

From 1City of Hope Comprehensive Cancer Center; 2Memorial Sloan-Kettering Cancer Center; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washingt… 04/15/2009 9.90 Blood
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Abstract

Bloomfield, Clara D

The Ohio State University 04/08/2009 9.90 Blood
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Abstract

Meshinchi, Soheil

Clinical Research Division 03/20/2009 9.90 Blood
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Abstract

Dombret, Hervé

Department of Hematology, Hôpital Edouard Herriot, Lyon 03/16/2009 9.90 Blood
The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 03/12/2009 9.90 Blood
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Abstract

Marcucci, Guido

The Ohio State University 02/11/2009 9.90 Blood
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Abstract

Weisdorf, Daniel J

University of Minnesota 01/28/2009 9.90 Blood
Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Abstract

Delwel, Ruud

Erasmus University Medical Center 01/26/2009 9.90 Blood
Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Abstract

Delwel, Ruud

Erasmus University Medical Center 01/23/2009 9.90 Blood
Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Abstract

Pui, Ching-Hon

St Jude Children's Research Hospital 01/08/2009 9.90 Blood
Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. Abstract

Relling, Mary V

St Jude Children's Research Hospital 12/09/2008 9.90 Blood
Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Abstract

Björkholm, Magnus

Genetic Epidemiology Branch, DCEG, NCI, 6120 Executive Blvd, Room 7124, MSC 7236, Bethesda, MD 20892-7236 11/19/2008 9.90 Blood
Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Abstract

Andreeff, Michael

University of Texas MD Anderson Cancer Center 10/28/2008 9.90 Blood
CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Abstract

Appelbaum, Frederick R

Clinical Research Division 10/16/2008 9.90 Blood
Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Abstract

Maciejewski, Jaroslaw P

Cleveland Clinic 10/02/2008 9.90 Blood
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Abstract

Delwel, Ruud

Erasmus University Medical Center 08/14/2008 9.90 Blood
A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects. Abstract

Weissman, Irving L

Stanford University School of Medicine 02/06/2013 9.81 Proceedings of the National Academy of Sciences of the United States of America
Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Abstract

Armstrong, Scott A

Harvard Medical School 03/06/2012 9.81 Proceedings of the National Academy of Sciences of the United States of America
Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Abstract

Chen, Sai-Juan

Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine 01/24/2011 9.81 Proceedings of the National Academy of Sciences of the United States of America
C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Abstract

Marcucci, Guido

The Ohio State University 04/05/2010 9.81 Proceedings of the National Academy of Sciences of the United States of America
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Abstract

Ley, Timothy J

Washington University School of Medicine 07/27/2009 9.81 Proceedings of the National Academy of Sciences of the United States of America
Acquired copy number alterations in adult acute myeloid leukemia genomes. Abstract

Weissman, Irving L

Stanford University School of Medicine 02/13/2009 9.81 Proceedings of the National Academy of Sciences of the United States of America
Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Abstract

Bloomfield, C D

The Ohio State University Comprehensive Cancer Center 12/11/2013 9.56 Leukemia
GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Abstract

Garcia-Manero, G

University of Texas MD Cancer Center 11/25/2013 9.56 Leukemia
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Abstract

van den Heuvel-Eibrink, M M

Erasmus MC-Sophia Children's Hospital 11/25/2013 9.56 Leukemia
miR-9 is a tumor suppressor in pediatric AML with t(8;21). Abstract

Haferlach, T

MLL Munich Leukemia Laboratory, Munich 08/20/2013 9.56 Leukemia
Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease. Abstract

Tien, H F

National Taiwan University 08/09/2013 9.56 Leukemia
Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Abstract

Carroll, M

University of Pennsylvania 07/04/2013 9.56 Leukemia
Induced differentiation of acute myeloid leukemia cells by activation of retinoid X and liver X receptors. Abstract

Bloomfield, C D

The Ohio State University Comprehensive Cancer Center 06/14/2013 9.56 Leukemia
A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Abstract

Estey, E H

University of Washington School of Medicine 06/12/2013 9.56 Leukemia
Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Abstract

Tefferi, A

Mayo Clinic 04/26/2013 9.56 Leukemia
Mutations and prognosis in primary myelofibrosis. Abstract

Tefferi, A

Mayo Clinic 04/22/2013 9.56 Leukemia
CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Abstract

Stegmaier, K

Harvard Medical School 03/28/2013 9.56 Leukemia
SYK regulates mTOR signaling in AML. Abstract

Tefferi, A

Mayo Clinic 03/27/2013 9.56 Leukemia
Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Abstract

Graubert, T A

Washington University 02/27/2013 9.56 Leukemia
Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Abstract

Andreeff, M

University of Texas M. D. Anderson Cancer Center 12/18/2012 9.56 Leukemia
HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML. Abstract

Armstrong, S A

Children's Hospital 12/13/2012 9.56 Leukemia
Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Abstract

Marcucci, G

The Ohio State University and The Ohio State University Comprehensive Cancer Center 11/26/2012 9.56 Leukemia
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Abstract

Armstrong, S A

Dana Farber Cancer Institute and Harvard Medical School 11/09/2012 9.56 Leukemia
Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Abstract

Ravandi, F

The University of Texas MD Anderson Cancer Center 11/08/2012 9.56 Leukemia
Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Abstract

Kantarjian, H M

The University of Texas 11/06/2012 9.56 Leukemia
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Abstract

Haferlach, T

MLL Munich Leukemia Laboratory, Munich 09/11/2012 9.56 Leukemia
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Abstract

Chen, S-J

Rui Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine 02/07/2012 9.56 Leukemia
Newly diagnosed acute lymphoblastic leukemia in China (I): abnormal genetic patterns in 1346 childhood and adult cases and their comparison with the reports from Western countries. Abstract

Chen, S-J

Rui Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine 02/02/2012 9.56 Leukemia
Newly diagnosed acute lymphoblastic leukemia in China (II): prognosis related to genetic abnormalities in a series of 1091 cases. Abstract

Andreeff, M

University of Texas M. D. Anderson Cancer Center 11/08/2011 9.56 Leukemia
MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Abstract

Tefferi, A

Mayo Clinic 10/28/2011 9.56 Leukemia
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Abstract

Andreeff, M

The University of Texas MD Anderson Cancer Center 09/09/2011 9.56 Leukemia
MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML. Abstract

Pui, C-H

St Jude Children's Research Hospital 08/26/2011 9.56 Leukemia
ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Abstract

Van den Heuvel-Eibrink, M M

Erasmus MC-Sophia Children's Hospital 05/13/2011 9.56 Leukemia
The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Abstract

Haferlach, T

MLL Munich Leukemia Laboratory, Munich 05/03/2011 9.56 Leukemia
Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Abstract

Graubert, T A

Washington University 03/18/2011 9.56 Leukemia
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Abstract

Haferlach, T

MLL Munich Leukemia Laboratory, Munich 01/14/2011 9.56 Leukemia
Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms. Abstract

Garcia-Manero, G

University of Texas MD Cancer Center 11/30/2010 9.56 Leukemia
Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Abstract

Tien, H-F

National Taiwan University Hospital 11/16/2010 9.56 Leukemia
The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Abstract

Tefferi, A

Mayo Clinic 11/12/2010 9.56 Leukemia
Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Abstract

Tefferi, A

Policlinico Universitario di Palermo 10/14/2010 9.56 Leukemia
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Abstract

van den Heuvel-Eibrink, M M

Erasmus MC-Sophia Children's Hospital 09/23/2010 9.56 Leukemia
High BRE expression in pediatric MLL-rearranged AML is associated with favorable outcome. Abstract

Mullighan, C G

St Jude Children's Research Hospital 08/26/2010 9.56 Leukemia
Genomic profiling of high-risk acute lymphoblastic leukemia. Abstract

Carroll, M

University of Pennsylvania 05/06/2010 9.56 Leukemia
BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia. Abstract

Tefferi, A

Mayo Clinic 04/29/2010 9.56 Leukemia
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Abstract

Tefferi, A

Mayo Clinic 04/22/2010 9.56 Leukemia
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Abstract

Graubert, T A

Washington University 04/08/2010 9.56 Leukemia
POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature. Abstract

Meshinchi, S

Clinical Research Division 04/08/2010 9.56 Leukemia
Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Abstract

van den Heuvel-Eibrink, M M

Erasmus MC-Sophia Children's Hospital 04/01/2010 9.56 Leukemia
EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Abstract

Döhner, H

University Hospital of Ulm 12/17/2009 9.56 Leukemia
Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. Abstract

Ravandi, F

The University of Texas MD Anderson Cancer Center 09/10/2009 9.56 Leukemia
Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Abstract

Carroll, M

University of Pennsylvania 07/23/2009 9.56 Leukemia
A robust xenotransplantation model for acute myeloid leukemia. Abstract

Chen, S-J

Rui Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine 05/21/2009 9.56 Leukemia
AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2. Abstract

Pui, C-H

St Jude Children's Research Hospital 03/12/2009 9.56 Leukemia
Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Abstract

Levine, R L

Mayo Clinic 03/05/2009 9.56 Leukemia
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Abstract

Ravandi, F

The University of Texas MD Anderson Cancer Center 02/26/2009 9.56 Leukemia
Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Abstract

Tien, H-F

National Taiwan University Hospital 02/19/2009 9.56 Leukemia
Acute myeloid leukemia bearing t(7;11)(p15;p15) is a distinct cytogenetic entity with poor outcome and a distinct mutation profile: comparative analysis of 493 adult patients. Abstract

Andreeff, Michael

University of Texas MD Anderson Cancer Center 07/25/2009 9.56 Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Abstract

Sung, Lillian

The Hospital for Sick Children 09/05/2012 9.15 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Association between corticosteroids and infection, sepsis, and infectious death in pediatric acute myeloid leukemia (AML): results from the Canadian infections in AML research group. Abstract

Andreeff, Michael

The University of Texas MD Anderson Cancer Center 03/09/2010 7.86 Cancer research
Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim. Abstract

Campana, Dario

National University of Singapore 04/21/2009 7.86 Cancer research
Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Abstract

Levine, Ross L

Memorial Sloan-Kettering Cancer Center 10/21/2010 7.80 Science translational medicine
Metabolic syndromes and malignant transformation: where the twain shall meet. Abstract

Marcucci, Guido

The Ohio State University 03/14/2013 7.74 Clinical cancer research : an official journal of the American Association for Cancer Research
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Abstract

Ebert, Benjamin L

Harvard Medical School 01/17/2013 7.74 Clinical cancer research : an official journal of the American Association for Cancer Research
New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice. Abstract

Mullighan, Charles G

University of California 05/16/2012 7.74 Clinical cancer research : an official journal of the American Association for Cancer Research
Advances in the genetics of high-risk childhood B-progenitor acute lymphoblastic leukemia and juvenile myelomonocytic leukemia: implications for therapy. Abstract

Mullighan, Charles G

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105 12/13/2010 7.74 Clinical cancer research : an official journal of the American Association for Cancer Research
New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice. Abstract

Ebert, Benjamin L

Harvard Medical School 06/29/2010 7.74 Clinical cancer research : an official journal of the American Association for Cancer Research
NF1 inactivation revs up Ras in adult acute myelogenous leukemia. Abstract

Garcia-Manero, Guillermo

The University of Texas MD Anderson Cancer Center 10/23/2010 7.45 Autophagy
The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Abstract

Sung, L

Pediatric Oncology Group of Ontario, Toronto 10/28/2012 6.43 Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Adolescents with acute lymphoblastic leukemia treated at pediatric versus adult hospitals. Abstract

Tien, H-F

National Taiwan University 08/06/2010 6.43 Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information. Abstract

Tien, H-F

National Taiwan University Hospital 03/08/2009 6.43 Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Prediction of fatal intracranial hemorrhage in patients with acute myeloid leukemia. Abstract

Estey, Elihu H

Clinical Research Division and Southwest Oncology Group Statistical Center 10/18/2013 6.42 Haematologica
Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study. Abstract

Bloomfield, Clara D

The Ohio State University 10/04/2013 6.42 Haematologica
Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 06/28/2013 6.42 Haematologica
Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Abstract

Falini, Brunangelo

University of Perugia 01/24/2013 6.42 Haematologica
Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Abstract

Weisdorf, Daniel J

University of Minnesota 09/14/2012 6.42 Haematologica
Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research. Abstract

Weisdorf, Daniel J

University of Minnesota 07/06/2012 6.42 Haematologica
Survival for older patients with acute myeloid leukemia: a population-based study. Abstract

Maciejewski, Jaroslaw P

Cleveland Clinic 07/06/2012 6.42 Haematologica
Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Abstract

Haferlach, Torsten

MLL Munich Leukemia Laboratory, Munich 06/24/2012 6.42 Haematologica
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases. Abstract

Ravandi, Farhad

The University of Texas M. D. Anderson Cancer Center 04/24/2012 6.42 Haematologica
Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Abstract

Haferlach, Torsten

MLL Munich Leukemia Laboratory, Munich 04/17/2012 6.42 Haematologica
Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow. Abstract

Appelbaum, Frederick R

and University of Washington School of Medicine 02/07/2012 6.42 Haematologica
Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 01/22/2012 6.42 Haematologica
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Abstract

Estey, Elihu H

Clinical Research Division and Southwest Oncology Group Statistical Center 12/01/2011 6.42 Haematologica
Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. Abstract

Döhner, Hartmut

Universitätsklinikum Ulm, Ulm 11/04/2011 6.42 Haematologica
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Abstract

Ganser, Arnold

Hannover Medical School 08/31/2011 6.42 Haematologica
Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Abstract

Haferlach, Torsten

MLL Munich Leukemia Laboratory, Munich 08/22/2011 6.42 Haematologica
Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA. Abstract

van den Heuvel-Eibrink, Marry M

Erasmus MC-Sophia Children's Hospital 07/26/2011 6.42 Haematologica
Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Abstract

Bloomfield, Clara D

The Ohio State University 06/09/2011 6.42 Haematologica
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Abstract

Haferlach, Torsten

MLL Munich Leukemia Laboratory, Munich 05/23/2011 6.42 Haematologica
Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 02/28/2011 6.42 Haematologica
Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Abstract

Heuser, Michael

Hannover Medical School 05/21/2010 6.42 Haematologica
IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Abstract

Tien, Hwei-Fang

National Taiwan University Hospital 03/10/2010 6.42 Haematologica
Changes in magnetic resonance bone marrow angiogenesis on day 7 after induction chemotherapy can predict outcome of acute myeloid leukemia. Abstract

van den Heuvel-Eibrink, Marry M

Erasmus MC-Sophia Children's Hospital 12/16/2009 6.42 Haematologica
Pharmacogenetic risk factors for altered bone mineral density and body composition in pediatric acute lymphoblastic leukemia. Abstract

Maciejewski, Jaroslaw P

Cleveland Clinic 10/01/2009 6.42 Haematologica
Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. Abstract

Falini, Brunangelo

Munich Leukemia Laboratory GmbH, Munich 12/09/2008 6.42 Haematologica
Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm. Abstract

Döhner, Konstanze

University Hospital of Ulm 12/04/2008 6.42 Haematologica
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Abstract

Mullighan, Charles G

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105 02/07/2011 6.00 Current topics in developmental biology
Genetic alterations targeting lymphoid development in acute lymphoblastic leukemia. Abstract

Sung, Lillian

The Hospital for Sick Children 11/13/2011 5.54 European journal of cancer (Oxford, England : 1990)
Treatment-related mortality in children with acute myeloid leukaemia in Central America: incidence, timing and predictors. Abstract

van den Heuvel-Eibrink, Marry M

Erasmus MC-Sophia Children's Hospital 03/16/2010 5.54 European journal of cancer (Oxford, England : 1990)
Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings technique. Abstract

Falini, Brunangelo

Munich Leukemia Laboratory GmbH, Munich 12/20/2012 5.36 Blood reviews
Mutational landscape of AML with normal cytogenetics: biological and clinical implications. Abstract

Tien, H-F

National Taiwan University Hospital 11/17/2011 5.04 British journal of cancer
Distinct association between aberrant methylation of Wnt inhibitors and genetic alterations in acute myeloid leukaemia. Abstract

Pabst, T

University of Bern 07/14/2010 5.04 British journal of cancer
The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML. Abstract

Sung, L

Children's Hospital of Eastern Ontario 03/17/2009 5.04 British journal of cancer
Incidence and predictors of treatment-related mortality in paediatric acute leukaemia in El Salvador. Abstract

Appelbaum, Frederick R

Clinical Research Division 10/28/2013 4.94 British journal of haematology
Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia. Abstract

Cortes, Jorge

The University of Texas MD Anderson Cancer Center 03/27/2013 4.94 British journal of haematology
Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Abstract

van den Heuvel-Eibrink, Marry M

Erasmus MC-Sophia Children's Hospital 10/01/2012 4.94 British journal of haematology
CBL mutations do not frequently occur in paediatric acute myeloid leukaemia. Abstract

Ravandi, Farhad

M.D. Anderson Cancer Center 02/24/2012 4.94 British journal of haematology
Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Abstract

Maciejewski, Jaroslaw P

Cleveland Clinic 04/12/2010 4.94 British journal of haematology
Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations. Abstract

Haferlach, Torsten

University Cancer Center Hamburg 03/16/2009 4.94 British journal of haematology
Current status of gene expression profiling in the diagnosis and management of acute leukaemia. Abstract

Levine, Ross L

Memorial Sloan-Kettering Cancer Center 11/27/2012 4.93 Current topics in microbiology and immunology
JAK-mutant myeloproliferative neoplasms. Abstract

Dombret, Hervé

Department of Hematology, Hôpital Edouard Herriot, Lyon 02/04/2011 4.78 Oncotarget
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Abstract

Kantarjian, Hagop

The University of Texas M. D. Anderson Cancer Center 01/10/2011 4.77 Cancer
Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Abstract

Kantarjian, Hagop

The University of Texas M. D. Anderson Cancer Center 11/08/2010 4.77 Cancer
Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study. Abstract

Tallman, Martin S

From 1City of Hope Comprehensive Cancer Center; 2Memorial Sloan-Kettering Cancer Center; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washingt… 10/25/2010 4.77 Cancer
Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Abstract

Cortes, Jorge

The University of Texas MD Anderson Cancer Center 10/19/2010 4.77 Cancer
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 10/19/2010 4.77 Cancer
Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Abstract

Kantarjian, Hagop M

The University of Texas M. D. Anderson Cancer Center 10/19/2010 4.77 Cancer
Monitoring molecular response in chronic myeloid leukemia. Abstract

Kantarjian, Hagop

The University of Texas M. D. Anderson Cancer Center 09/30/2010 4.77 Cancer
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 09/15/2010 4.77 Cancer
Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Abstract

Ravandi, Farhad

The University of Texas M. D. Anderson Cancer Center 08/27/2010 4.77 Cancer
Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Abstract

Dombret, Herve

Department of Hematology, Hôpital Edouard Herriot, Lyon 08/10/2010 4.77 Cancer
Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Abstract

Garcia-Manero, Guillermo

The University of Texas MD Anderson Cancer Center 07/29/2010 4.77 Cancer
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 06/24/2010 4.77 Cancer
Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Abstract

Garcia-Manero, Guillermo

The University of Texas MD Anderson Cancer Center 05/04/2010 4.77 Cancer
Characteristics of pericardial effusions in patients with leukemia. Abstract

Garcia-Manero, Guillermo

The University of Texas MD Anderson Cancer Center 04/26/2010 4.77 Cancer
Cause of death in patients with lower-risk myelodysplastic syndrome. Abstract

Dombret, Herve

Department of Hematology, Hôpital Edouard Herriot, Lyon 03/29/2010 4.77 Cancer
Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. Abstract

Kantarjian, Hagop M

The University of Texas M. D. Anderson Cancer Center 02/26/2010 4.77 Cancer
Adult acute lymphoblastic leukemia: concepts and strategies. Abstract

Kantarjian, Hagop

The University of Texas M. D. Anderson Cancer Center 12/16/2009 4.77 Cancer
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 08/26/2009 4.77 Cancer
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 08/26/2009 4.77 Cancer
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 08/11/2009 4.77 Cancer
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Abstract

Kantarjian, Hagop

The University of Texas M. D. Anderson Cancer Center 07/10/2009 4.77 Cancer
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Abstract

Kantarjian, Hagop M

The University of Texas M. D. Anderson Cancer Center 06/29/2009 4.77 Cancer
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 05/25/2009 4.77 Cancer
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Abstract

Ravandi, Farhad

The University of Texas M. D. Anderson Cancer Center 01/05/2009 4.77 Cancer
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Abstract

Tien, Hwei-Fang

National Taiwan University Hospital 11/20/2013 4.67 American journal of hematology
IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. Abstract

Tien, Hwei-Fang

National Taiwan University Hospital 11/20/2013 4.67 American journal of hematology
Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression. Abstract

Tefferi, Ayalew

Mayo Clinic 10/24/2013 4.67 American journal of hematology
Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management. Abstract

Tien, Hwei-Fang

National Taiwan University Hospital 09/03/2013 4.67 American journal of hematology
Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression. Abstract

Tefferi, Ayalew

Mayo Clinic 05/22/2013 4.67 American journal of hematology
Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Abstract

Estey, Elihu H

Clinical Research Division and Southwest Oncology Group Statistical Center 03/25/2013 4.67 American journal of hematology
Acute myeloid leukemia: 2013 update on risk-stratification and management. Abstract

Garcia-Manero, Guillermo

The University of Texas MD Anderson Cancer Center 03/20/2013 4.67 American journal of hematology
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Abstract

Tefferi, Ayalew

Mayo Clinic 01/18/2013 4.67 American journal of hematology
Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Abstract

Garcia-Manero, Guillermo

The University of Texas MD Anderson Cancer Center 10/31/2012 4.67 American journal of hematology
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Abstract

Kantarjian, Hagop

The University of Texas M. D. Anderson Cancer Center 10/23/2012 4.67 American journal of hematology
Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Abstract

Garcia-Manero, Guillermo

The University of Texas MD Anderson Cancer Center 06/14/2012 4.67 American journal of hematology
Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Abstract

Tefferi, Ayalew

Mayo Clinic 05/22/2012 4.67 American journal of hematology
Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. Abstract

Tefferi, Ayalew

Mayo Clinic 05/06/2012 4.67 American journal of hematology
Sole abnormalities of chromosome 7 in myeloid malignancies: spectrum, histopathologic correlates, and prognostic implications. Abstract

Tefferi, Ayalew

Mayo Clinic 03/28/2012 4.67 American journal of hematology
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Abstract

Tefferi, Ayalew

Mayo Clinic 02/14/2012 4.67 American journal of hematology
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Abstract

Garcia-Manero, Guillermo

The University of Texas MD Anderson Cancer Center 01/07/2012 4.67 American journal of hematology
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. Abstract

Estey, Elihu H

Clinical Research Division and Southwest Oncology Group Statistical Center 12/19/2011 4.67 American journal of hematology
Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Abstract

Tefferi, Ayalew

Mayo Clinic 11/17/2011 4.67 American journal of hematology
Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: clinical correlates and prognostic studies. Abstract

Garcia-Manero, Guillermo

The University of Texas MD Anderson Cancer Center 05/19/2011 4.67 American journal of hematology
Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management. Abstract

Tefferi, Ayalew

Mayo Clinic 04/27/2011 4.67 American journal of hematology
Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients. Abstract

Garcia-Manero, Guillermo

The University of Texas MD Anderson Cancer Center 04/20/2011 4.67 American journal of hematology
Prediction model for mortality after intracranial hemorrhage in patients with leukemia. Abstract

Tefferi, Ayalew

Mayo Clinic 03/28/2011 4.67 American journal of hematology
Autosomal monosomies among 24,262 consecutive cytogenetic studies: prevalence, chromosomal distribution and clinicopathologic correlates of sole abnormalities. Abstract

Tefferi, Ayalew

Mayo Clinic 02/25/2011 4.67 American journal of hematology
Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management. Abstract

Maciejewski, Jaroslaw P

Cleveland Clinic 12/24/2010 4.67 American journal of hematology
Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. Abstract

Tefferi, Ayalew

Mayo Clinic and Mayo Clinic College of Medicine 03/31/2010 4.67 American journal of hematology
Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution. Abstract

Campana, Dario

National University of Singapore 02/05/2013 4.52 Current opinion in hematology
Should evaluation for minimal residual disease be routine in acute myeloid leukemia? Abstract

Campana, Dario

National University of Singapore 06/06/2012 4.52 Current opinion in hematology
Minimal residual disease monitoring in childhood acute lymphoblastic leukemia. Abstract

Weisdorf, Daniel J

Mayo Clinic Rochester 10/12/2011 4.52 Current opinion in hematology
Allogeneic stem cell transplantation in first complete remission. Abstract

Marcucci, Guido

The Ohio State University 05/26/2009 4.52 Current opinion in hematology
Molecular signatures in acute myeloid leukemia. Abstract

Döhner, Konstanze

University Hospital of Ulm 05/26/2009 4.52 Current opinion in hematology
Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. Abstract

Maciejewski, Jaroslaw P

Cleveland Clinic 12/05/2008 4.52 Current opinion in hematology
Diagnosis and therapy of neutropenia in large granular lymphocyte leukemia. Abstract

Tallman, Martin S

From 1City of Hope Comprehensive Cancer Center; 2Memorial Sloan-Kettering Cancer Center; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washingt… 12/16/2013 4.41 Journal of the National Comprehensive Cancer Network : JNCCN
Postconsolidation maintenance and monitoring in patients with acute promyelocytic leukemia. Abstract

Tallman, Martin S

From 1City of Hope Comprehensive Cancer Center; 2Memorial Sloan-Kettering Cancer Center; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washingt… 09/13/2013 4.41 Journal of the National Comprehensive Cancer Network : JNCCN
Acute myeloid leukemia, version 2.2013. Abstract

Appelbaum, Frederick R

and University of Washington School of Medicine 03/11/2011 4.41 Journal of the National Comprehensive Cancer Network : JNCCN
Identifying older patients with acute myeloid leukemia who may be candidates for reduced-intensity hematopoietic cell transplantation. Abstract

Tallman, M S

Memorial Sloan-Kettering Cancer Center 06/19/2012 4.33 Current cancer drug targets
Novel and emerging drugs for acute myeloid leukemia. Abstract

Kantarjian, Hagop

The University of Texas M. D. Anderson Cancer Center 07/09/2010 4.23 Drugs
Current and future management options for myelodysplastic syndromes. Abstract

Haferlach, Torsten

University Cancer Center Hamburg 10/07/2010 4.10 Current opinion in oncology
Molecular genetics in acute myeloid leukemia. Abstract

Löwenberg, Bob

University Hospital La Fe 10/12/2009 4.10 Current opinion in oncology
FLT3 inhibition as a targeted therapy for acute myeloid leukemia. Abstract

Sung, Lillian

The Hospital for Sick Children 09/06/2013 4.09 PloS one
Reasons for non-completion of health related quality of life evaluations in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Abstract

Garcia-Manero, Guillermo

The University of Texas MD Anderson Cancer Center 08/15/2013 4.09 PloS one
Overexpression of the toll-like receptor (TLR) signaling adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromes. Abstract

Sung, Lillian

The Hospital for Sick Children 04/26/2013 4.09 PloS one
Infectious events prior to chemotherapy initiation in children with acute myeloid leukemia. Abstract

Ley, Timothy J

Siteman Cancer Center 10/08/2012 4.09 PloS one
Expression and function of PML-RARA in the hematopoietic progenitor cells of Ctsg-PML-RARA mice. Abstract

Sung, Lillian

The Hospital for Sick Children 08/22/2012 4.09 PloS one
Low socioeconomic status is associated with prolonged times to assessment and treatment, sepsis and infectious death in pediatric fever in El Salvador. Abstract

Graubert, Timothy A

Washington University School of Medicine 11/17/2010 4.07 BMC genomics
Integrated genomics of susceptibility to alkylator-induced leukemia in mice. Abstract

van den Heuvel-Eibrink, Marry M

Erasmus MC-Sophia Children's Hospital 11/25/2013 4.02 Bone
Bone mineral density at diagnosis determines fracture rate in children with acute lymphoblastic leukemia treated according to the DCOG-ALL9 protocol. Abstract

van den Heuvel-Eibrink, M M

Erasmus MC-Sophia Children's Hospital 10/16/2010 4.02 Bone
Germline variation in the MTHFR and MTRR genes determines the nadir of bone density in pediatric acute lymphoblastic leukemia: a prospective study. Abstract

Meshinchi, Soheil

Clinical Research Division 11/19/2013 3.99 Seminars in hematology
Somatic characterization of pediatric acute myeloid leukemia using next-generation sequencing. Abstract

Kantarjian, Hagop

The University of Texas M. D. Anderson Cancer Center 10/03/2013 3.99 Seminars in hematology
Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Abstract

Chen, Sai-Juan

Rui Jin Hospital affiliated with Shanghai Jiao Tong University School of Medicine 03/19/2013 3.99 Seminars in hematology
DNA methyltransferases in hematologic malignancies. Abstract

Armstrong, Scott A

Harvard Medical School 12/22/2008 3.99 Seminars in hematology
Leukemia stem cells and human acute lymphoblastic leukemia. Abstract

Weisdorf, Daniel J

University of Minnesota 09/06/2013 3.87 Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Providing personalized prognostic information for adult leukemia survivors. Abstract

Weisdorf, Daniel J

University of Minnesota 03/16/2012 3.87 Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival. Abstract

Weisdorf, Daniel J

Mayo Clinic Rochester 07/31/2011 3.87 Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Abstract

Weisdorf, Daniel J

Mayo Clinic Rochester 11/01/2010 3.87 Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Abstract

Dombret, H

University Paris 7 03/19/2012 3.75 Bone marrow transplantation
Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML. Abstract

Weisdorf, D J

University of Minnesota 05/23/2011 3.75 Bone marrow transplantation
Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. Abstract

Ganser, A

Hannover Medical School 06/14/2010 3.75 Bone marrow transplantation
Prognostic factors in allo-SCT of elderly patients with AML. Abstract

Haferlach, T

MLL Munich Leukemia Laboratory, Munich 04/13/2009 3.75 Bone marrow transplantation
Interactive diagnostics in the indication to allogeneic SCT in AML. Abstract

Ravandi, F

The University of Texas MD Anderson Cancer Center 01/19/2009 3.75 Bone marrow transplantation
Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Abstract

Pui, C-H

St Jude Children's Research Hospital 07/30/2009 3.68 AJNR. American journal of neuroradiology
Voxel-based analysis of T2 hyperintensities in white matter during treatment of childhood leukemia. Abstract

Sung, Lillian

The Hospital for Sick Children 01/13/2014 3.58 The Pediatric infectious disease journal
Predictors and outcomes of viridans group streptococcal infections in pediatric acute myeloid leukemia: from the Canadian infections in AML research group. Abstract

Sung, Lillian

The Hospital for Sick Children 07/10/2013 3.58 The Pediatric infectious disease journal
Clostridium difficile infection in pediatric acute myeloid leukemia: from the Canadian Infections in Acute Myeloid Leukemia Research Group. Abstract

Sung, Lillian

The Hospital for Sick Children 11/25/2009 3.58 The Pediatric infectious disease journal
Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia. Abstract

Maciejewski, Jaroslaw P

Cleveland Clinic 01/31/2012 3.50 Seminars in oncology
Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. Abstract

Levine, Ross L

Memorial Sloan-Kettering Cancer Center 09/29/2011 3.50 Seminars in oncology
Molecular biology of myelodysplastic syndromes. Abstract

Ebert, Benjamin L

Harvard Medical School 09/29/2011 3.50 Seminars in oncology
Molecular dissection of the 5q deletion in myelodysplastic syndrome. Abstract

Garcia-Manero, Guillermo

The University of Texas MD Anderson Cancer Center 09/29/2011 3.50 Seminars in oncology
Integrating care for patients with lower risk myelodysplastic syndrome. Abstract

Garcia-Manero, Guillermo

The University of Texas MD Anderson Cancer Center 09/29/2011 3.50 Seminars in oncology
Treatment of higher-risk myelodysplastic syndrome. Abstract

Heuser, Michael

Hannover Medical School 03/27/2012 3.31 Genes, chromosomes & cancer
Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. Abstract

Haferlach, Torsten

University Cancer Center Hamburg 12/08/2011 3.31 Genes, chromosomes & cancer
ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events. Abstract

Haferlach, Torsten

University Cancer Center Hamburg 11/10/2011 3.31 Genes, chromosomes & cancer
Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia. Abstract

Döhner, Konstanze

University Hospital of Ulm 11/11/2010 3.31 Genes, chromosomes & cancer
Molecular characterization of AML with ins(21;8)(q22;q22q22) reveals similarity to t(8;21) AML. Abstract

Maciejewski, Jaroslaw P

Cleveland Clinic 02/15/2010 3.31 Genes, chromosomes & cancer
Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis. Abstract

Ravandi, Farhad

M.D. Anderson Cancer Center 03/22/2011 3.21 Expert opinion on emerging drugs
Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 09/20/2012 3.21 Expert opinion on pharmacotherapy
Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. Abstract

Ravandi, Farhad

The University of Texas M. D. Anderson Cancer Center 04/20/2012 3.16 Future oncology (London, England)
Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial. Abstract

Dombret, Hervé

Department of Hematology, Hôpital Edouard Herriot, Lyon 10/26/2009 3.16 Future oncology (London, England)
Clofarabine for the treatment of adult acute myeloid leukemia. Abstract

Sung, Lillian

The Hospital for Sick Children 06/04/2013 3.01 BMC cancer
Infections in pediatric acute promyelocytic leukemia: from the canadian infections in acute myeloid leukemia research group. Abstract

Tien, Hwei-Fang

National Taiwan University Hospital 03/08/2013 3.01 BMC cancer
Hierarchical cluster analysis of immunophenotype classify AML patients with NPM1 gene mutation into two groups with distinct prognosis. Abstract

Garcia-Manero, Guillermo

The University of Texas MD Anderson Cancer Center 11/13/2013 2.92 Leukemia research
Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry. Abstract

Haferlach, Torsten

University Cancer Center Hamburg 12/10/2012 2.92 Leukemia research
Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia. Abstract

Tallman, Martin S

Memorial Sloan-Kettering Cancer Center 10/24/2012 2.92 Leukemia research
Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Abstract

Haferlach, Torsten

University Cancer Center Hamburg 09/15/2012 2.92 Leukemia research
Molecular genetics in myelodysplastic syndromes. Abstract

Pabst, Thomas

University Hospital and University of Berne 06/23/2012 2.92 Leukemia research
The relapse risk of AML patients undergoing autologous transplantation correlates with the stem cell mobilizing potential. Abstract

Dombret, Hervé

Department of Hematology, Hôpital Edouard Herriot, Lyon 05/28/2012 2.92 Leukemia research
Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial. Abstract

Haferlach, Torsten

University Cancer Center Hamburg 05/01/2012 2.92 Leukemia research
Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course. Abstract

Bhatia, Ravi

Division of Hematopoietic Stem Cell and Leukemia Research and. 04/12/2012 2.92 Leukemia research
Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors. Abstract

Tallman, Martin S

Memorial Sloan-Kettering Cancer Center 12/15/2011 2.92 Leukemia research
Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia. Abstract

van den Heuvel-Eibrink, Marry M

Erasmus MC-Sophia Children's Hospital 10/12/2010 2.92 Leukemia research
KIAA1524: A novel MLL translocation partner in acute myeloid leukemia. Abstract

Maciejewski, Jaroslaw P

Cleveland Clinic 03/23/2010 2.92 Leukemia research
Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Abstract

Pabst, Thomas

University Hospital and University of Berne 12/16/2009 2.92 Leukemia research
Complexity of miR-223 regulation by CEBPA in human AML. Abstract

Garcia-Manero, Guillermo

The University of Texas MD Anderson Cancer Center 08/13/2009 2.92 Leukemia research
Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor. Abstract

Haferlach, Torsten

University Cancer Center Hamburg 05/02/2009 2.92 Leukemia research
Characterization of a new myeloid leukemia cell line with normal cytogenetics (CG-SH). Abstract

Haferlach, Torsten

MLL Munich Leukemia Laboratory, Munich 10/01/2010 2.91 Experimental hematology
A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: an analysis in 1135 patients with AML and 187 healthy controls. Abstract

Kantarjian, Hagop

The University of Texas M. D. Anderson Cancer Center 05/05/2009 2.91 Experimental hematology
Proteomics-based prediction of clinical response in acute myeloid leukemia. Abstract

Andreeff, Michael

The University of Texas MD Anderson Cancer Center 04/19/2011 2.87 Journal of cellular biochemistry
Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells. Abstract

Kantarjian, Hagop M

The University of Texas M. D. Anderson Cancer Center 10/05/2012 2.85 European journal of clinical pharmacology
Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia. Abstract

Mullighan, Charles G

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105 01/14/2011 2.83 Current opinion in pediatrics
How new advances in genetic analysis are influencing the understanding and treatment of childhood acute leukemia. Abstract

Falini, Brunangelo

University of Perugia 03/18/2013 2.80 Protein science : a publication of the Protein Society
Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization. Abstract

Kantarjian, Hagop M

The University of Texas M. D. Anderson Cancer Center 11/18/2013 2.65 Expert review of anticancer therapy
Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. Abstract

Ravandi, Farhad

M.D. Anderson Cancer Center 10/16/2013 2.64 Best practice & research. Clinical haematology
Relapsed acute myeloid leukemia: why is there no standard of care? Abstract

Appelbaum, Frederick R

Clinical Research Division 10/16/2013 2.64 Best practice & research. Clinical haematology
Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia. Abstract

Levine, Ross L

Memorial Sloan-Kettering Cancer Center 10/15/2013 2.64 Best practice & research. Clinical haematology
Molecular pathogenesis of AML: translating insights to the clinic. Abstract

Garcia-Manero, Guillermo

The University of Texas MD Anderson Cancer Center 10/25/2012 2.64 Best practice & research. Clinical haematology
Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy. Abstract

Mullighan, Charles G

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105 11/06/2011 2.64 Best practice & research. Clinical haematology
Genomic profiling of B-progenitor acute lymphoblastic leukemia. Abstract

Appelbaum, Frederick R

Clinical Research Division 11/02/2011 2.64 Best practice & research. Clinical haematology
The role of hematopoietic cell transplantation as therapy for myelodysplasia. Abstract

Haferlach, Torsten

University Cancer Center Hamburg 08/12/2010 2.64 Best practice & research. Clinical haematology
The role of multiparameter flow cytometry for disease monitoring in AML. Abstract

Levine, Ross L

Memorial Sloan-Kettering Cancer Center 12/04/2009 2.64 Best practice & research. Clinical haematology
Mechanisms of mutations in myeloproliferative neoplasms. Abstract

Haferlach, Torsten

University Cancer Center Hamburg 08/24/2009 2.64 Best practice & research. Clinical haematology
Gene expression profiling in acute myeloid leukaemia (AML). Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 10/22/2013 2.64 Cancer
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Abstract

Pui, Ching-Hon

St Jude Children's Research Hospital 03/01/2013 2.64 Cancer
Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia. Abstract

Sung, Lillian

The Hospital for Sick Children 11/16/2012 2.64 Cancer
Outcome of children treated for relapsed acute lymphoblastic leukemia in Central America. Abstract

Ravandi, Farhad

The University of Texas M. D. Anderson Cancer Center 06/15/2012 2.64 Cancer
Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. Abstract

Ravandi, Farhad

M.D. Anderson Cancer Center 05/08/2012 2.64 Cancer
Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 02/27/2012 2.64 Cancer
Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Abstract

Kantarjian, Hagop

The University of Texas M. D. Anderson Cancer Center 01/31/2012 2.64 Cancer
Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Abstract

Kantarjian, Hagop M

The University of Texas MD Anderson Cancer Center 01/26/2012 2.64 Cancer
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Abstract

Garcia-Manero, Guillermo

The University of Texas MD Anderson Cancer Center 01/17/2012 2.64 Cancer
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system. Abstract

Kantarjian, Hagop

The University of Texas M. D. Anderson Cancer Center 10/21/2011 2.64 Cancer
Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Abstract

Estey, Elihu H

Stanford University School of Medicine 09/16/2011 2.64 Cancer
Impact of residual normal metaphases in core binding factor acute myeloid leukemia. Abstract

Appelbaum, Frederick R

Clinical Research Division 09/16/2011 2.64 Cancer
Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 04/26/2011 2.64 Cancer
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. Abstract

Sung, Lillian

The Hospital for Sick Children 03/28/2011 2.64 Cancer
Treatment-related mortality in children with acute lymphoblastic leukemia in Central America. Abstract

Cortes, Jorge

The University of Texas MD Anderson Cancer Center 02/11/2011 2.64 Cancer
FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era? Abstract

Heuser, Michael

Hannover Medical School 12/12/2012 2.62 Annals of hematology
Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia. Abstract

Heuser, Michael

Hannover Medical School 04/10/2012 2.62 Annals of hematology
Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes. Abstract

Haferlach, Torsten

MLL Munich Leukemia Laboratory, Munich 03/02/2010 2.62 Annals of hematology
Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies. Abstract

Ganser, Arnold

Hannover Medical School 11/17/2011 2.61 European journal of haematology
Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. Abstract

Tefferi, Ayalew

Mayo Clinic 11/30/2009 2.61 European journal of haematology
Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations. Abstract

Tefferi, Ayalew

Mayo Clinic 01/09/2009 2.61 European journal of haematology
Conventional cytogenetics in myelofibrosis: literature review and discussion. Abstract

Sung, Lillian

The Hospital for Sick Children 01/15/2011 2.60 Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Pneumatosis intestinalis in children with acute lymphoblastic leukemia and acute myeloid leukemia. Abstract

Haferlach, Torsten

University Cancer Center Hamburg 02/14/2014 2.58 Leukemia & lymphoma
Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing. Abstract

Sung, Lillian

The Hospital for Sick Children 11/19/2013 2.58 Leukemia & lymphoma
Early deaths in pediatric acute leukemia: a population-based study. Abstract

Marcucci, Guido

The Ohio State University 11/01/2013 2.58 Leukemia & lymphoma
Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia. Abstract

Ravandi, Farhad

M.D. Anderson Cancer Center 10/09/2013 2.58 Leukemia & lymphoma
Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Abstract

Ravandi, Farhad

M.D. Anderson Cancer Center 08/28/2013 2.58 Leukemia & lymphoma
Acute myeloid leukemia in the elderly: do we know who should be treated and how? Abstract

Pabst, Thomas

Universitätsspital Basel , Basel 05/02/2013 2.58 Leukemia & lymphoma
Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07). Abstract

Heuser, Michael

Hannover Medical School 11/15/2011 2.58 Leukemia & lymphoma
Update on cytogenetic and molecular changes in myelodysplastic syndromes. Abstract

Haferlach, Torsten

MLL Munich Leukemia Laboratory, Munich 01/11/2011 2.58 Leukemia & lymphoma
Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells. Abstract

Ravandi, Farhad

M.D. Anderson Cancer Center 04/28/2010 2.58 Leukemia & lymphoma
Late relapses in acute myeloid leukemia: analysis of characteristics and outcome. Abstract

Sung, Lillian

The Hospital for Sick Children 04/28/2010 2.58 Leukemia & lymphoma
Gastrointestinal complications in children with acute myeloid leukemia. Abstract

Kantarjian, Hagop

The University of Texas M. D. Anderson Cancer Center 08/13/2013 2.56 Journal of cancer research and clinical oncology
The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. Abstract

Estey, Elihu H

Stanford University School of Medicine 09/03/2012 2.55 Current oncology reports
Acute myeloid leukemia with normal cytogenetics. Abstract

Carroll, Martin

University of Pennsylvania 11/03/2010 2.55 Current oncology reports
Targeted signal transduction therapies in myeloid malignancies. Abstract

Campana, Dario

National University of Singapore 06/26/2013 2.53 Cytometry. Part B, Clinical cytometry
Detection of minimal residual disease in pediatric acute lymphoblastic leukemia. Abstract

Haferlach, Torsten

University Cancer Center Hamburg 01/02/2013 2.53 Cytometry. Part B, Clinical cytometry
Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms. Abstract

Haferlach, Torsten

MLL Munich Leukemia Laboratory, Munich 12/05/2011 2.53 Cytometry. Part B, Clinical cytometry
Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia. Abstract

Haferlach, Torsten

MLL Munich Leukemia Laboratory, Munich 10/06/2009 2.53 Cytometry. Part B, Clinical cytometry
Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia. Abstract

Garcia-Manero, Guillermo

The University of Texas MD Anderson Cancer Center 11/29/2011 2.38 Epigenomics
Histone methylation in myelodysplastic syndromes. Abstract

Sung, L

Children's Hospital of Eastern Ontario 02/26/2013 2.25 Mycoses
Invasive fungal infections in paediatric acute myeloid leukaemia. Abstract

Tallman, Martin S

Roosevelt Hospital Center 05/22/2012 2.14 Medical oncology (Northwood, London, England)
Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17). Abstract

Levine, Ross L

Memorial Sloan-Kettering Cancer Center 08/21/2012 2.07 Hematology/oncology clinics of North America
Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms. Abstract

Cortes, Jorge

The University of Texas M. D. Anderson Cancer Center 10/19/2011 2.07 Hematology/oncology clinics of North America
Chronic myeloid leukemia: mechanisms of resistance and treatment. Abstract

Ebert, Benjamin L

Harvard Medical School 04/02/2010 2.07 Hematology